Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A new market report highlights upcoming patent expirations for Johnson & Johnson’s cancer medicines Imbruvica and Darzalex, underscoring the broader “patent cliff” risk facing large pharmaceutical companies.
THE APEX TIMES
THE APEX TIMES
Ahead of Johnson & Johnson’s third-quarter results, a market preview urges investors to look past the headline consensus numbers and instead focus on the specific operating and segment metrics that often drive how the quarter is judged.
THE APEX TIMES
A recent market commentary points to upside in the long-term growth outlook for Johnson & Johnson, while offering limited disclosed detail on the specific drivers.
THE APEX TIMES
A recent market note points to Johnson & Johnson’s track record of earnings surprises and the presence of two factors that often precede upside quarters, putting focus on the company’s next earnings report.
THE APEX TIMES
JNJ closed at $271.19 on Sept. 1, up 2.01% from the prior session, according to Yahoo Finance market data.
THE APEX TIMES
A fresh jury finding in a Louisiana talc-related mesothelioma case underscores how Johnson & Johnson (JNJ) remains exposed to trial-by-trial outcomes in its long-running litigation over alleged asbestos contamination in talc products.
THE APEX TIMES
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
THE APEX TIMES
A new industry report says palmoplantar pustulosis is drawing more clinical attention and research into targeted biologic therapies, naming Johnson & Johnson among the companies profiled.
THE APEX TIMES
A recent market-leaning roundup says Johnson & Johnson holds stakes across 15 publicly traded stocks, with one investment standing out as the clearest leader by the post’s internal ranking.
